The Role of Alemtuzumab in Nonmyeloablative Hematopoietic Transplantation

Seminars in Oncology

Volumn 33, Issue SUPPL. 5, 2006, Pages 36-43

  Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE;

ARTICLE; AUTOTRANSPLANTATION; CANCER CELL; CLINICAL TRIAL; COMORBIDITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; MORTALITY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T CELL DEPLETION; VIREMIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 33646552389     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.028     Document Type: Article

References (33)

1. Hale G., Slavin S., Goldman J.M., et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?. Bone Marrow Transplant 30 (2002) 797-804
2. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
3. Horowitz M., Gale R., Sondel P., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
4. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite. induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
5. Maloney D.G., Sandmaier B.M., Mackinnon S., et al. Non-myeloablative transplantation. Hematology (Am Soc Hematol Educ Program) (2002) 392-421
6. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies. Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
7. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens. reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
8. Hale G., Jacobs P., Wood L., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26 (2000) 69-76
9. Chakrabarti S., MacDonald D., Hale G., et al. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 121 (2003) 109-118
10. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations. Relevance for early adoptive immunotherapy and infectious complications. Blood 102 (2003) 404-406
11. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101 (2003) 441-445
12. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
13. Dreger P., Stilgenbauer S., Boettcher S., et al. Long-term disease control of poor-risk chronic lymphocytic leukemia (CLL) by allogeneic stem cell transplantation with nonmyeloablative conditioning (NST). Interim results of a prospective study (2005) Presented at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12
14. Bensinger W.I., and Storb R. Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 5 (2001) 67-86
15. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation. A meta-analysis. J Clin Oncol 19 (2001) 3685-3691
16. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
17. Champlin R.E., Schmitz N., Horowitz M.M., et al., IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95 (2000) 3702-3709
18. Mavromatis B., and Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 21 (2003) 1874-1881
19. Hale G., Rebello P., Brettman L.R., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004) 948-955
20. Hale G. Alemtuzumab in stem cell transplantation. Med Oncol 19 suppl (2002) S33-S47
21. Ratzinger G., Reagan J.L., Heller G., et al. Differential CD52 expression by distinct myeloid dendritic cell subsets. Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 101 (2003) 1422-1429
22. Chakrabarti S., Hale G., and Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation. Where do we go from here?. Transplant Proc 36 (2004) 1225-1227
23. Khouri I.F., Albitar M., Saliba R.M., et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies. Decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 33 (2004) 833-837
24. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
25. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab. Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
26. Faulkner R.D., Craddock C., Byrne J.L., et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases. GVHD, toxicity, and survival in 65 patients. Blood 103 (2004) 428-434
27. Chakraverty R., Robinson S., Peggs K., et al. Excessive T-cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 28 (2001) 827-834
28. Klangsinsirikul P., Carter G.I., Byrne J.L., et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 99 (2002) 2586-2591
29. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
30. Dartigeas C., Degenne M., Senecal D., et al. Efficacy and safety of alemtuzumab in patients with relapsed B-cell chronic lymphocytic leukemia after autologous stem cell transplantation. Blood 104 (2004) 2509 (abstr)
31. Montillo M., Tedeschi A., Miqueleiz S., et al. Consolidation with alemtuzumab after a response to fludarabine in patients with CLL. Confirmation of the efficacy to purge residual disease. Leuk Lymphoma 46 suppl 1 (2005) 93 (abstr)
32. Rawstron A., Villamor N., Ritgen M., et al. International standardized approach to molecular and flow cytometric residual disease monitoring in CLL. Leuk Lymphoma 46 suppl 1 (2005) 100 (abstr)
33. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation. Potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363